Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study

Lipton, Richard B.; Munjal, Sagar; Buse, Dawn C.; Bennett, Alix; Fanning, Kristina M.; Burstein, Rami; Reed, Michael L.

doi:10.1111/head.13115

Cited by 55 publications

(52 citation statements)

References 53 publications

(106 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment of migraine, and particularly chronic migraine, remains challenging, and numerous therapeutic drugs are non‐specific, sometimes inefficient, with side effects and contraindications (Serrano et al ., ; Schytz et al ., ). Cutaneous allodynia in chronic migraine is associated with inadequate outcomes for any anti‐migraine medication (Lipton et al ., ). Furthermore, a significant proportion of chronic migraine cases are due to anti‐migraine medication abuse or misuse (Bigal and Lipton, ; Lipton et al ., ), highlighting the need for new medications, including new prophylactic approaches to prevent the chronification process.…”

Section: Discussionmentioning

confidence: 97%

Effects of systemic inhibitors of acid‐sensing ion channels 1 (ASIC1) against acute and chronic mechanical allodynia in a rodent model of migraine

Verkest

Piquet

Diochot

et al. 2018

British J Pharmacology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

Effects of systemic inhibitors of acid‐sensing ion channels 1 (ASIC1) against acute and chronic mechanical allodynia in a rodent model of migraine

Verkest

Piquet

Diochot

et al. 2018

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…Cutaneous allodynia has been associated with an increased risk of attack recurrence and migraine chronicity . Cutaneous allodynia also predicts inadequate 2‐hour pain‐free and 24‐hour pain relief outcomes . Diagnostic vigilance remains important, and all consulting patients, especially women, should be queried about the presence of allodynia.…”

Section: Discussionmentioning

confidence: 99%

“…21,41,42,47 Cutaneous allodynia also predicts inadequate 2-hour pain-free and 24-hour pain relief outcomes. 46,[48][49][50] Diagnostic vigilance remains important, and all consulting patients, especially women, should be queried about the presence of allodynia. Unilateral pain and headaches that are pounding or pulsatile are statistically more common in women than men, but the differences are small and may not be clinically relevant.…”

Section: Discussionmentioning

confidence: 99%

Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences

Lipton

Munjal²,

Alam³

et al. 2018

Headache

Self Cite

124

192

View full text Add to dashboard Cite

Objectives To summarize the baseline methods for the Migraine in America Symptoms and Treatment (MAST) Study and evaluate gender differences in sociodemographics and headache features; consultation and diagnosis patterns; and patterns of acute and preventive treatment use for migraine among study participants. Background The MAST Study is a longitudinal, internet‐based panel study of symptoms, approaches to management, and unmet treatment needs among US adults with migraine. This analysis focuses on the initial cross‐sectional survey, conducted beginning in 2016, and is intended to update results from earlier national epidemiologic surveys of people with migraine in the United States. Methods Respondents to the MAST Study were recruited from a US nationwide online research panel. Stratified random sampling identified a representative cohort of adults (aged ≥18 years). We administered a validated diagnostic screener based on modified ICHD‐3 beta criteria to identify individuals with migraine averaging at least 1 monthly headache day (MHD) over the previous 3 months. A baseline assessment evaluated sociodemographic and headache features, patterns of consultation and diagnosis, and use of acute and preventive medications for migraine. Frequency data and chi‐square contrasts (P < .05) were used to compare respondents based on gender. Results Baseline survey data (N = 95,821) identified 18,353 respondents who met criteria for migraine, including 15,133 (women n = 11,049, men n = 4084) reporting at least 1 MHD for the preceding 3 months. The mean age of the sample was 43.1 (13.6) years; 73.0% of respondents were women, and 81.0% were Caucasian. Compared with men, women were younger (46.1 vs 42.0 years; P < .001); had more MHDs (5.6 vs 5.3; P < .001); and were more likely to report moderate or severe headache‐related disability (45.9% vs 35.8%; P < .001) and cutaneous allodynia (43.7% vs 29.5%; P < .001). The lifetime rate of medical consultation for headache was 79.8% overall and slightly higher in women than in men. Women were more likely than men to have been diagnosed with migraine (48.3% vs 38.8%, P < .001). While 95.1% of people with migraine currently used acute treatment, the majority (58.9%) used over‐the‐counter (OTC) drugs to the exclusion of prescription drugs, while 11.3% used exclusively prescription drugs, and 20.5% used both. Among acute prescription medication users, women were more likely than men to take triptans (17.7% vs 14.3%, P < .001), while men were more likely than women to take opioids (14.5% vs 9.2%, P < .001). Oral formulations were used predominately (92.7% of the medication users), but men were more likely to use nasal sprays (13.6% vs 9.4%, P < .001) and injectables (7.9% vs 3.4%, P < .001). Men (14.5%) were also significantly more likely than women (10.4%) to be taking daily oral preventive medication (P < .001). Conclusions The MAST Study identified a large sample of women and men with migraine from a sampling frame that broadly resembles the US population. Low participation r...

show abstract

“…In reference to allodynia, which has been considered a pathophysiological correlate of clinical progression, we observed a statistically significant and greater reduction in those patients with a decrease in headache frequency of ≥50%. We also analyzed other migraine features, observing higher proportions of aura, both visual and sensory, after 10 years.…”

Section: Discussionmentioning

confidence: 68%

How Does Migraine Change After 10 Years? A Clinical Cohort Follow‐Up Analysis

et al. 2020

View full text Add to dashboard Cite

Objective.-To describe the 10-year evolution of a cohort of migraine patients, focusing on prognostic factors of improvement.Background.-Migraine is one of the most prevalent and disabling diseases and migraineurs often want to know about the evolutionary timeline of their condition. Yet, data from longitudinal studies with a long-term follow-up is scarce.Methods.-This is a 10-year longitudinal study. In 2008, we recruited 1109 consecutive migraine patients who answered an initial survey. In 2018, we did a follow-up. We compared initial and final (after 10 years) data. A reduction ≥50% in Headache days/month was considered as improvement. A comparative study was carried out to identify predictors of improvement or no improvement.Results.-After 10 years, 380 patients completed the survey (34.3% of the initial cohort), 77.1% (293/380) were women; mean age 41.0 ± 10.6 years and 73.7% (280/380) had an initial diagnosis of episodic migraine (EM). After 10 years, 48.2% (183/380) of patients did not have a medical follow-up of their migraine; 47.4% (180/380) decreased ≥50% in frequency, which increased the proportion of EM (73.7% vs 87.4%) (P < .001) as compared to the initial results. Factors independently associated with improvement were: a baseline frequency >10 days/month (OR[ 95%]: 3.04 [1.89, 4.89]; P < .001), nonsmoking (2.13 [1.23, 3.67]; P = .006) and a medical follow-up for migraine (2.45 [1.54, 3.90]; P < .001). Additionally, after 10 years, we observed a reduction in the use of preventive treatment (48.7% vs 23.5%) and an increase in monotherapy (42.2% vs 72.7%) (P < .001).Conclusion.-After 10 years, in almost half of the patients who answered the survey, migraine improved. Other than the natural pathophysiology of migraine, having a medical follow-up and healthy habits such as nonsmoking were independent factors associated with improvement.

show abstract

Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study

Cited by 55 publications

References 53 publications

Effects of systemic inhibitors of acid‐sensing ion channels 1 (ASIC1) against acute and chronic mechanical allodynia in a rodent model of migraine

Effects of systemic inhibitors of acid‐sensing ion channels 1 (ASIC1) against acute and chronic mechanical allodynia in a rodent model of migraine

Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences

How Does Migraine Change After 10 Years? A Clinical Cohort Follow‐Up Analysis

Contact Info

Product

Resources

About